For adults and children with hemophilia A
AFSTYLA, with a twice-weekly dosing option, delivers long-lasting bleed protection using a novel single-chain Factor VIII design
Twice-weekly dosing can mean fewer infusions each week.† Ask your doctor if twice-weekly dosing is right for you.
FDA approved for 2 to 3 times
ZERO median annualized spontaneous bleeds* were reported in clinical trials for children and adults regardless of dosing schedule.
Regardless of age and dosing schedule.
*AsBR= annualized spontaneous bleeding rate.
Compared to dosing 3 times a week.
The safety of AFSTYLA was shown in 258 previously treated children, adolescents, and adults over 19,545 exposure days.
Zero inhibitors in clinical trials with previously treated people.
*AsBR=annualized spontaneous bleeding rate.†Compared to dosing 3 times a week.
Sign up today
CSL Behring makes it easy to start on AFSTYLA with a simple 3-step process. You’ll also have access to comprehensive support services that can make a meaningful difference in the lives of people with bleeding disorders.
You can also call 1-800-676-4266 to get detailed information about the services available to you.
After more than 30 YEARS of experience in bleeding disorders, CSL Behring remains committed to developing innovative therapies for the people who need them